[
  {
    "ts": null,
    "headline": "A Look At Vertex Pharmaceuticals (VRTX) Valuation As Shares Trade Near Vestra Fair Value Estimate",
    "summary": "Vertex Pharmaceuticals stock: context for recent performance Vertex Pharmaceuticals (VRTX) has attracted attention recently as investors weigh its current share price of $496.83 against company fundamentals, including annual revenue of US$12.0b and net income of US$3.95b. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been positive, with a 1-day share price return of 3.48% and a 90-day share price return of 14.58%. The 5-year total shareholder return of 134.38% points...",
    "url": "https://finnhub.io/api/news?id=d0f741db6334281d8219cc840bf591fd712fb5bab94ef0fc6a46c8b05a3b56cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772305632,
      "headline": "A Look At Vertex Pharmaceuticals (VRTX) Valuation As Shares Trade Near Vestra Fair Value Estimate",
      "id": 139265882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals stock: context for recent performance Vertex Pharmaceuticals (VRTX) has attracted attention recently as investors weigh its current share price of $496.83 against company fundamentals, including annual revenue of US$12.0b and net income of US$3.95b. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been positive, with a 1-day share price return of 3.48% and a 90-day share price return of 14.58%. The 5-year total shareholder return of 134.38% points...",
      "url": "https://finnhub.io/api/news?id=d0f741db6334281d8219cc840bf591fd712fb5bab94ef0fc6a46c8b05a3b56cd"
    }
  },
  {
    "ts": null,
    "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
    "url": "https://finnhub.io/api/news?id=d94cacec40d8bf68f98f0616ed737720b9ab95b18723e069473fb6502b70dd3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772291278,
      "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
      "id": 139264510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
      "url": "https://finnhub.io/api/news?id=d94cacec40d8bf68f98f0616ed737720b9ab95b18723e069473fb6502b70dd3a"
    }
  },
  {
    "ts": null,
    "headline": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]",
    "url": "https://finnhub.io/api/news?id=653b4e5a7f04df8527a7a218eb2f38329d491c5fee52ff881bd864a124f5cd19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772284184,
      "headline": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory",
      "id": 139262932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]",
      "url": "https://finnhub.io/api/news?id=653b4e5a7f04df8527a7a218eb2f38329d491c5fee52ff881bd864a124f5cd19"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout",
    "summary": "Vertex Pharmaceuticals (VRTX) shows a strong technical setup for a potential breakout, combining a confirmed uptrend with a high-quality consolidation pattern.",
    "url": "https://finnhub.io/api/news?id=5cb598f7b493879e65fef6327cc039773b2a65b5e621a624c82b46209cb1ee31",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772277098,
      "headline": "Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout",
      "id": 139261908,
      "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
      "related": "VRTX",
      "source": "ChartMill",
      "summary": "Vertex Pharmaceuticals (VRTX) shows a strong technical setup for a potential breakout, combining a confirmed uptrend with a high-quality consolidation pattern.",
      "url": "https://finnhub.io/api/news?id=5cb598f7b493879e65fef6327cc039773b2a65b5e621a624c82b46209cb1ee31"
    }
  },
  {
    "ts": null,
    "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "summary": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
    "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772266200,
      "headline": "10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)",
      "id": 139262332,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=70d1f60145dc5d34c3a46f1b5cca72e4c80f57870a091a466ae46368aa1ad457"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
    "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
    "url": "https://finnhub.io/api/news?id=90cc248b7acdcf9c6c36af148e5b666bdc87c11be493049305ccbe32b3546dd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772263315,
      "headline": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
      "id": 139260974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
      "url": "https://finnhub.io/api/news?id=90cc248b7acdcf9c6c36af148e5b666bdc87c11be493049305ccbe32b3546dd6"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
    "url": "https://finnhub.io/api/news?id=6ef4eb069efa6009f72ebb053c5f3b55af92e3bce2ca38a076c84871390b449a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772263307,
      "headline": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
      "id": 139260975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
      "url": "https://finnhub.io/api/news?id=6ef4eb069efa6009f72ebb053c5f3b55af92e3bce2ca38a076c84871390b449a"
    }
  }
]